The Hatch-Waxman and IPR Strategy in Light of Recent Case Decisions: Addressing Emerging Issues
Recording Available: Thursday, August 06, 2020
Inter partes review (IPR) proceedings have been an attractive ground for drug companies seeking to challenge the patentability of pharmaceutical products. The IPR allows challengers to maximize the streamlined process of the Patent Trial and Appeal Board (PTAB) while also taking advantage of the benefits provided by the Hatch-Waxman Act. Given this backdrop, the number of challenges utilizing the IPR process is predicted to continuously climb this year and beyond.
Practitioners must, therefore, ensure that they are prepared in this rapidly evolving climate. The need to stay on top of the recent legal developments to devise effective litigation strategies is more crucial than ever. Some of the 2019 rulings which lawyers should consider in developing strategies this 2020 include Return Mail v. U.S. Postal Service, Regents of the Univ. of Minn. v. LSI Corp., and AVX Corp. v. Presidio Components Inc.
Join a panel of key thought leaders and professionals assembled by The Knowledge Group as they delve into an in-depth analysis of the significant issues resulting from the interaction between IPR proceedings and the Hatch-Waxman Act. Speakers will also provide practical strategies in bringing out the best in these lawsuits in light of the current trends and recent court rulings.
Key topics include:
- The Unique Interplay Between Hatch-Waxman and IPR
- Recent Case Decisions
- Current and Emerging Issues
- Effective Litigation Strategies
Who Should Attend:
- Patent Lawyers and Agents
- Biotech/Pharma Industry Lawyers
- In–House Counsels
- Intellectual Property Specialists and Managers
- Chief Compliance Officers
Tony Pezzano is a partner in the New York offices of DLA Piper LLP (US). Tony has successfully tried numerous cases in federal district courts and the ITC involving technology innovation across a diverse range of industries. Tony has been lead counsel for brand pharmaceutical companies in over two dozen filed Hatch-Waxman cases during the past ten years involving antibiotic, antiviral, antifungal, anticoagulant, and anti-organ transplant rejection drug products. Tony has also represented both Complainants and Respondents in ITC Section 337 investigations involving biologics, SeaDoos/WaveRunners, wireless communication devices, including mobile phones and tablets, computer routers and Segways/hoverboards. Few attorneys, if any, can match Tony’s record of obtaining both injunctions in Hatch-Waxman cases as well as exclusion and cease and desist orders in ITC Section 337 investigations. Tony is Past President (2009) of the ITC Trial Lawyers Association.
Print and review course materials
Method Of Presentation:
Areas of Professional Practice
NY Category of CLE Credit:
Areas of Professional Practice
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
UNLIMITED 1 Year Pass for only $199
About DLA Piper
With over 90 offices, DLA Piper’s highly-regarded IP practice is recognized as a leading firm across the world. Our patent litigation practice ranks among the most active practices in complex multi-jurisdictional patent disputes before US district courts, the ITC and in key foreign jurisdictions. DLA Piper's patent lawyers also counsel innovative companies on strategic patent prosecution in the US and worldwide. Our trademarks practice manages more than 70,000 marks in over 150 countries, representing many of the top 100 global brands. Many of our IP and Technology lawyers have been recognized as leaders by numerous publications such as Chambers, The Legal 500, The National Law Journal, Law360, The Daily Journal, Managing IP, Intellectual Asset Management, and World Trademark Review.